Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03011541

Stem Cell Ophthalmology Treatment Study II

Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
500 (estimated)
Sponsor
MD Stem Cells · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.

Detailed description

Eyes with loss of vision from retinal or optic nerve conditions generally considered irreversible will be treated with a combination of injections of autologous bone marrow derived stem cells isolated from the bone marrow using standard medical and surgical practices. Retinal conditions may include degenerative, ischemic or physical damage ( examples may include macular degeneration, hereditary retinal dystrophies such as retinitis pigmentosa, stargardt, non-perfusion retinopathies, post retinal detachment. Optic Nerve conditions may include degenerative, ischemic or physical damage ( examples may include optic nerve damage from glaucoma, compression, ischemic optic neuropathy, optic atrophy ). Injections may include retrobulbar, subtenon, intravitreal, intraocular, subretinal and intravenous. Patients will be followed for 12 months with serial comprehensive eye examinations including relevant imaging and diagnostic ophthalmic testing.

Conditions

Interventions

TypeNameDescription
PROCEDUREArm 1Procedure/ Surgery: RB (Retrobulbar) Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC) Procedure/Surgery: ST (Subtenon) Subtenon injection of Bone Marrow Derived Stem Cells (BMSC) Procedure/Surgery: IV (Intravenous) Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)

Timeline

Start date
2016-01-01
Primary completion
2026-07-31
Completion
2027-07-31
First posted
2017-01-05
Last updated
2025-03-20

Locations

4 sites across 3 countries: United States, Austria, United Arab Emirates

Source: ClinicalTrials.gov record NCT03011541. Inclusion in this directory is not an endorsement.